ArticleScientific reports2025
The impact of gamma interferon on BK virus candidate microRNAs and related miRNAs in kidney transplant patients with BK infection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computational Design and Biopharmaceutical Evaluation of a Chimeric Nanoparticle Vaccine for Targeted Delivery against BK Polyomavirus.Pharmaceutical research · 2026Article
- Ten tips on management of BK nephropathy in kidney transplant patients.Clinical kidney journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney transplant recipients (KTRs) with impaired immune systems may develop BKV nephropathy (BKVN). BKVN and allograft rejection may harm transplanted kidneys. BKV replicates via miR-B1-5p and 3p in order to escape from host's immunological response. BKV alters KTR and viral gene expression and miRNA profiles. In an inflammatory setting, IFN-γ may initiate the removal of pathogens by inducing an immune response. It has antiviral immunity, which may prevent the virus from replicating by preventing the synthesis of BK virus proteins. Antiviral miRNAs like miR-29a are also produced in response to IFN-γ activation. Thus, we investigated these modifications as putative biomarkers for evaluating viral infection and the regulatory web that arises from their expression during infection and the emergence of post-transplant problems. This study was carried out on KTRs. Our research, which aimed to quantify and examine the amounts of cellular miRNA-29a, IFN-γ gene, BKV-miR-B1-5p and 3p from urine and blood in KT patient groups, has the potential to guide future research in the field. Patients with BKVN (BK-), patients without an active BKV infection (BK-), patients with a history of transplant rejection (Reject), patients without an active history of transplant rejection (Non reject), and a control group were among these groups. The Syber green real-time PCR was employed for the measurements and analysis. The findings of our investigation demonstrated that BK virus-caused kidney tissue damage (tissue), patients with an active BK virus infection (BK+), and KTRs who had previously experienced transplant rejection all showed less IFN-γ gene expression in comparison with control. These patients showed upper levels of miR-29a gene expression than the control group. Furthermore, these patients' gene expressions of miR-B1-5p and 3p showed higher in comparison with those of the control group. To date, there is no report on the effect of IFN-γ on the expression of BK polyomavirus miRNAs and related miRNAs in kidney transplant recipients with nephropathy compared to kidney transplant recipients without nephropathy in the Iranian population. Therefore, the results of this study can be used as a strategy to combat viral infections and pathogenesis caused by BK polyomavirus in kidney transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.